Table I.
Cohort 1 patient characteristics.
| Characteristics | gBRCAm (n=16) | BRCAwt (n=25) | All (n=41) |
|---|---|---|---|
| Age, median (range), years | 52 (28–71) | 65 (49–73) | 65 (28–73) |
| Tumor status | |||
| Primary stage III/IV | 0 | 0 | 0 |
| Recurrent | 16 (100%) | 25 (100%) | 41 (100%) |
| Histology | |||
| HGSOC | 16 (100%) | 25 (100%) | 41 (100%) |
| Clear cell | 0 | 0 | 0 |
| Years from initial diagnosis | |||
| <5 years | 10 (63%) | 12 (48%) | 22 (54%) |
| ≥5 years | 6 (37%) | 13 (52%) | 19 (46%) |
| Number of previous lines of therapy, median (range) | 5 (2–8) | 7 (3–14) | 6 (2–14) |
| Platinum sensitivity | |||
| Platinum-sensitive recurrent disease | 5 (31%) | 8 (32%) | 13 (32%) |
| Platinum-resistant recurrent disease | 11 (69%) | 17 (68%) | 28 (68%) |
| Prior bevacizumab | |||
| Yes | 5 (31%) | 19 (76%) | 24 (58%) |
| No | 11 (69%) | 6 (24%) | 17 (42%) |
| Prior immune checkpoint inhibitors | 0 | 0 | 0 |
gBRCAm, germline BRCA mutation; BRCAwt, germline BRCA wild-type; HGSOC, high grade serous ovarian carcinoma.